The Association Between BRCA1 Expression and ER/PR Status in Breast Cancer Patients in NTB

Baiq Nurhandini Wulandari; Novrita Padauleng; Rizka Vidya Lestari; Baiq Ratna Kumaladewi

doi:10.29303/jbt.v25i4a.10745

The Association Between BRCA1 Expression and ER/PR Status in Breast Cancer Patients in NTB

Authors

Baiq Nurhandini Wulandari , Novrita Padauleng , Rizka Vidya Lestari , Baiq Ratna Kumaladewi

DOI:

10.29303/jbt.v25i4a.10745

Published:

2025-12-21

Issue:

Vol. 25 No. 4a (2025): Special Issue

Keywords:

BRCA1, ER, PR, invasive breast carcinoma, NTB

Articles

Downloads

pdf

How to Cite

Wulandari, B. N., Padauleng, N., Lestari, R. V., & Kumaladewi, B. R. (2025). The Association Between BRCA1 Expression and ER/PR Status in Breast Cancer Patients in NTB. Jurnal Biologi Tropis, 25(4a), 522–532. https://doi.org/10.29303/jbt.v25i4a.10745

Download Citation

Downloads

Download data is not yet available.

Abstract

Breast cancer is the most prevalent cancer among women in Indonesia, including in Nusa Tenggara Barat (NTB). Breast Cancer 1 (BRCA1) plays an important role in DNA repair and cell cycle regulation. Altered BRCA1 expression has been associated with the biological characteristics of breast cancer, including estrogen receptor (ER) and progesterone receptor (PR) status, both of which are crucial markers in determining molecular subtypes and predicting responses to hormonal therapy. However, previous studies regarding the association between BRCA1 expression and ER/PR status have shown inconsistent results. This study employed a cross-sectional design involving 50 patients who met the inclusion criteria, namely invasive breast carcinoma patients who had not received chemotherapy. BRCA1 expression was assessed using immunohistochemical staining, with a cut-off of BRCA1 positivity defined as >20% nuclear staining. ER/PR status was obtained from patients’ medical records archived in the Anatomical Pathology Laboratory of NTB Provincial Hospital in 2022–2023. Data processing and analysis were performed using the Chi-square test with a significance level of p < 0.05. Breast cancer patients in NTB demonstrated a balanced distribution of BRCA1 expression, with 50% positive and 50% negative. The majority of patients had ER/PR-positive expression (50%). Among patients with negative BRCA1 expression, 32% were classified as ER/PR-positive subtype. There was no significant association between BRCA1 expression and ER/PR status in breast cancer patients in NTB (p = 0.842). There is no significant association between BRCA1 expression and ER/PR status in breast cancer patients in NTB.

References

Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., Perou, C. M., Regan, M. M., Rimm, D. L., Symmans, W. F., Torlakovic, E. E., Varella, L., Viale, G., Weisberg, T. F., McShane, L. M., & Wolff, A. C. (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. Journal of Clinical Oncology, 38(12), 1346–1366. https://doi.org/10.1200/JCO.19.02309

Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023). A basic review on estrogen receptor signaling pathways in breast cancer. International Journal of Molecular Sciences, 24(7). https://doi.org/10.3390/ijms24076834

Dauphine, C., Moazzez, A., Neal, J. C., Chlebowski, R. T., & Ozao-Choy, J. (2020). Single hormone receptor-positive breast cancers have distinct characteristics and survival. Annals of Surgical Oncology, 27(12), 4687–4694. https://doi.org/10.1245/s10434-020-08898-5

Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., Olivotto, I. A., Bégin, L. R., & Narod, S. A. (2004). Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: The influence of age, grade, and histological type. Clinical Cancer Research, 10(6), 2029–2034. https://doi.org/10.1158/1078-0432.CCR-03-1061

Harahap, W. A., Arisanty, D., Khambri, D., Yanwirasti, & Mubarika, S. (2015). Metilasi promoter gen BRCA1 dan pengaruhnya terhadap karakteristik kanker payudara premenopause sporadik etnis Minang. CDK-226, 42(3), 186–190.

Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019). Breast cancer. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-019-0111-2

Hedau, S., Batra, M., Singh, U. R., et al. (2015). Ekspresi protein BRCA1 dan BRCA2 serta korelasinya dengan stadium klinis pada kanker payudara. Journal of Cancer Research and Therapeutics, 11, 158–163.

Hussein, I. A., Ahmed, S. T., Hameedi, A. D., Naji, R. Z., Alharbawi, L., Alkhaytt, M., & Pity, I. S. (2020). Immunohistochemical expression of BRCA1 protein, ER, PR and Her2/neu in breast cancer: A clinicopathological study. Asian Pacific Journal of Cancer Prevention, 21(4), 1025–1029. https://doi.org/10.31557/APJCP.2020.21.4.1025

Kim, S. W., Roh, J., & Park, C. S. (2016). Immunohistochemistry for pathologists: Protocols, pitfalls, and tips. Journal of Pathology and Translational Medicine, 50(6), 411–418. https://doi.org/10.4132/jptm.2016.08.08

Kumar, M., Sahu, R. K., Goyal, A., Sharma, S., Kaur, N., Mehrotra, R., Singh, U. R., & Hedau, S. (2017). BRCA1 promoter methylation and expression—Associations with ER+, PR+ and HER2+ subtypes of breast carcinoma. Asian Pacific Journal of Cancer Prevention, 18(12), 3293–3299. https://doi.org/10.22034/APJCP.2017.18.12.3293

Li, Z., Wei, H., Li, S., Wu, P., & Mao, X. (2022). The role of progesterone receptors in breast cancer. Drug Design, Development and Therapy, 16, 305–314. https://doi.org/10.2147/DDDT.S336643

Liaw, A. E., Wresnindyatsih, W., Nita, S., Murti, K., & Santoso, B. (2021). Hubungan antara ekspresi reseptor estrogen, progesteron dan Ki67 dengan karakteristik klinikopatologi pada karsinoma payudara subtipe Luminal A. Sriwijaya Journal of Medicine, 4(3), 203–213. https://doi.org/10.32539/sjm.v4i3.139

Lim, Y. X., Lim, Z. L., Ho, P. J., & Li, J. (2022). Breast cancer in Asia: Incidence, mortality, early detection, mammography programs, and risk-based screening initiatives. Cancers, 14(17). https://doi.org/10.3390/cancers14174218

Lu, Z., Yang, J., Feng, Y., & Ming, J. (2025). Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer. BMC Cancer, 25(1). https://doi.org/10.1186/s12885-025-14451-y

Ma, Y., Fan, S., Hu, C., Meng, Q., Fuqua, S. A., Pestell, R. G., Tomita, Y. A., & Rosen, E. M. (2010). BRCA1 regulates acetylation and ubiquitination of estrogen receptor-α. Molecular Endocrinology, 24(1), 76–90. https://doi.org/10.1210/me.2009-0218

Ma, Y., Katiyar, P., Jones, L. P., Fan, S., Zhang, Y., Furth, P. A., & Rosen, E. M. (2006). The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Molecular Endocrinology, 20(1), 14–34. https://doi.org/10.1210/me.2004-0488

Mouttet, D., Laé, M., Caly, M., Gentien, D., Carpentier, S., Peyro-Saint-Paul, H., Vincent-Salomon, A., Rouzier, R., Sigal-Zafrani, B., Sastre-Garau, X., & Reyal, F. (2016). Estrogen-receptor, progesterone-receptor and HER2 status determination in invasive breast cancer: Concordance between immunohistochemistry and MapQuantTM microarray based assay. PLoS ONE, 11(2), 1–13. https://doi.org/10.1371/journal.pone.0146474

Naimi, A., Saberi, F., & Amjadi, E. (2025). Immunohistochemical analysis of clinicopathological predictors for BRCA1 protein alterations in invasive breast carcinoma: A cross-sectional study. https://doi.org/10.34172/ipp.2025.43787

Rahayuwati, L., Rizal, I. A., Pahria, T., Lukman, M., & Juniarti, N. (2020). Pendidikan kesehatan tentang pencegahan penyakit kanker dan menjaga kualitas kesehatan. Media Karya Kesehatan, 3(1), 59–69. https://doi.org/10.24198/mkk.v3i1.26629

Rahmawati, Y., Setyawati, Y., Widodo, I., Ghozali, A., & Purnomosari, D. (2018). Molecular subtypes of Indonesian breast carcinomas—Lack of association with patient age and tumor size. Asian Pacific Journal of Cancer Prevention, 19(1), 161–166. https://doi.org/10.22034/APJCP.2018.19.1.161

Sharma, M., Khanna, M., Manjari, M., Madan, M., Singh, T., & Garg, T. (2016). Immunohistochemical characteristics of breast cancer with comparative study of BRCA1, ER, PR, BCL2, P53 and Ki-67: A population-based study. Annals of Pathology and Laboratory Medicine, 3(6).

Sleighholma, R., Neilsena, B. K., Elkhatiba, S., Floresa, L., Dukkipatia, S., Zhaoa, R., Choudhurya, S., Gardnera, B., Carmichaela, J., Smithb, L., Benniona, N., Wahla, A., & Bainea, M. (2021). Persentase reseptor hormon positif pada kanker payudara memberikan nilai prognostik: Studi satu lembaga, 13(1), 9–19.

Smolarz, B., Zadrożna Nowak, A., & Romanowicz, H. (2022). Breast cancer—Epidemiology, classification, pathogenesis and treatment: A literature review. Cancers, 14(10). https://doi.org/10.3390/cancers14102569

Suanjaya, M. A., Sherliyanah, S., & Utami, S. (2021). Prevalence and characteristics of breast cancer patients in Mataram City for the 2015–2020 period. Jurnal Aisyah: Jurnal Ilmu Kesehatan, 6(2), 403–408. https://doi.org/10.30604/jika.v6i2.958

Tanos, T., Rojo, L. J., Echeverria, P., & Brisken, C. (2012). ER and PR signaling nodes during mammary gland development. Breast Cancer Research, 14(4). https://doi.org/10.1186/bcr3166

Teixeira, L. A., & Candido Dos Reis, F. J. (2020). Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: A systematic review. Journal of Clinical Pathology, 73(4), 191–196. https://doi.org/10.1136/jclinpath-2019-206276

Trabert, B., Sherman, M. E., Kannan, N., & Stanczyk, F. Z. (2019). Progesterone and breast cancer. Endocrine Reviews, 41(2), 320–344. https://doi.org/10.1210/endrev/bnz001

Tuteja, R. K., Bagga, N., Agarwal, P., Mehrotra, R., & Singh, K. R. (2021). Immunohistochemical expression of ER, PR, HER2, Ki67, CK5/6, and BRCA1 in non-familial breast cancer and its correlation with clinicopathological parameters. Indian Journal of Pathology and Oncology, 8(1), 111–119. https://doi.org/10.18231/j.ijpo.2021.022

Varol, U., Kucukzeybek, Y., Alacacioglu, A., Somali, I., Altun, Z., Aktas, S., & Tarhan, M. O. (2018). BRCA genes: BRCA 1 and BRCA 2. Journal of B.U.ON., 23(4), 862–866.

Varshney, A., Juneja, K., Kumar, R., Singla, M., & Sharma, P. (2019). BRCA1 expression and its association with histological typing, grade, ER, PR, HER2 in carcinoma of breast. Indian Journal of Pathology and Oncology, 6(3), 376–380. https://doi.org/10.18231/j.ijpo.2019.073

Verma, D., Agarwal, K., & Tudu, S. (2018). Expression of BRCA1 and its relation with estrogen receptor, progesterone receptor and HER2/neu in breast carcinoma on trucut biopsy specimens. Indian Journal of Pathology and Microbiology, 61(1), 31–38. https://doi.org/10.4103/IJPM.IJPM_39316

Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2020). Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases. BMJ, 371. https://doi.org/10.1136/bmj.m3873

Wang, L., & Di, L. J. (2014). BRCA1 and estrogen/estrogen receptor in breast cancer: Where do they interact? International Journal of Biological Sciences, 10(5), 563–573. https://doi.org/10.7150/ijbs.8579

Warjianto, W., Soewoto, W., Alifianto, U., & Wujoso, H. (2020). Hubungan reseptor estrogen, reseptor progesteron dan ekspresi Her-2/Neu dengan grading histopatologi pada pasien kanker payudara di RSUD dr. Moewardi Surakarta. Smart Medical Journal, 3(2), 96. https://doi.org/10.13057/smj.v3i2.35228

Wilkinson, L., & Gathani, T. (2022). Understanding breast cancer as a global health concern. British Journal of Radiology, 95(1130), 7–9. https://doi.org/10.1259/BJR.20211033

Xu, X., Li, M., Hu, J., Chen, Z., Yu, J., Dong, Y., Sun, C., & Han, J. (2018). Somatic mitochondrial DNA D-loop mutations in meningioma: Preliminary data. Journal of Cancer Research and Therapeutics, 14(7), 1525–1534. https://doi.org/10.4103/jcrt.JCRT

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.

The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.

Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.

The Association Between BRCA1 Expression and ER/PR Status in Breast Cancer Patients in NTB

Authors

DOI:

Published:

Issue:

Keywords:

Articles

Downloads

How to Cite

Downloads

Abstract

References

License

Most read articles by the same author(s)

Similar Articles

Menu

Manuscript Template

visitor

Keywords

Mitra Kerja sama

Open Access Journals

Contact Us

Information

Share & Follow